Moneycontrol PRO

Buy Zydus Wellness; target of Rs 2250: Sharekhan

Sharekhan is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated July 29, 2022.

July 31, 2022 / 02:41 PM IST

"India’s specialty chemicals industry is a decadal growth opportunity and it is still not too late to participate in the value creation process. We prefer CRAMS/CSM players Navin Fluorine (Navin) and PI Industries (PI) as they provide long-term earnings visibility. We also like UPL due to robust growth outlook and reducing debt concerns and SRF due to rising contribution from the chemicals business," JM Financial research report.

  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Zydus Wellness

Zydus Wellness Limited’s (Zydus) reported higher-than-expected Q1FY2023 performance. Revenue/adjusted PAT grew by 16.6%/6.8% y-o-y. Volume growth stood at 10.3%. Margins down y-o-y due to sustained input cost inflation. Zydus gained/maintained market share/leadership position in most product categories. Focus is on sustained market share gains in key brands. Summer brands, Glucon D and Nycil, delivered strong double-digit growth after two years of lull. Management is targeting double-digit revenue growth over the next two years, aided by distribution expansion and product innovation.


We maintain Buy with an unchanged PT of Rs. 2,250. The stock trades at 27.7x/20.0x its FY2023E/FY2024E earnings, which is at a discount to some large peers.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Zydus Wellness - 290722 - khan

Broker Research
first published: Jul 31, 2022 02:39 pm
ISO 27001 - BSI Assurance Mark